CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis )
Also on site :
- Deaths reported during protests in Kenya (VIDEO)
- Man accused of pointing gun at troopers during I-90 standoff set to be arraigned
- Bianca Jagger, 80, Stuns in Breathtaking White Flapper Look Straight Out of 'The Great Gatsby'